Literature DB >> 20649849

Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis.

Antonella Marte1, Anna Cavallero, Sara Morando, Antonio Uccelli, Maurizio Raiteri, Ernesto Fedele.   

Abstract

We have investigated the spontaneous and the depolarisation-induced release of [(3)H]D-aspartate ([(3)H]D-ASP), a non-metabolisable analogue of glutamate, in spinal cord slices, synaptosomes and gliosomes from mice with experimental autoimmune encephalomyelitis (EAE) at 13, 21 and 55 days post-immunisation (d.p.i.), representing onset, peak and chronic phases of the pathology. At 13 and 21 d.p.i., the KCl-evoked, calcium-dependent overflow of [(3)H]D-ASP in spinal cord slices was significantly lower (30-40%), whereas at 55 d.p.i. it was significantly higher (30%), than that elicited in matched controls. When the release was measured from spinal cord synaptosomes and gliosomes in superfusion, a different picture emerged. The spontaneous and the KCl(15 mM)-induced release of [(3)H]D-ASP were significantly increased both in synaptosomes (17% and 45%, respectively) and gliosomes (26% and 25%, respectively) at 21, but not at 13, d.p.i. At 55 d.p.i., the KCl-induced [(3)H]D-ASP release was significantly increased (40%) only in synaptosomes. Finally, uptake of [(3)H]D-ASP was markedly (50-60%) increased in spinal cord synaptosomes, but not in gliosomes, obtained from EAE mice at 21 d.p.i., whereas no differences could be detected at 13 d.p.i. Our data indicate that glutamatergic neurotransmission is altered in the spinal cord of EAE mice.
© 2010 The Authors. Journal Compilation © 2010 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649849     DOI: 10.1111/j.1471-4159.2010.06923.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease.

Authors:  Silvia Di Prisco; Elisa Merega; Tommaso Bonfiglio; Guendalina Olivero; Chiara Cervetto; Massimo Grilli; Cesare Usai; Mario Marchi; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

Review 2.  Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.

Authors:  Georgia Mandolesi; Antonietta Gentile; Alessandra Musella; Diego Fresegna; Francesca De Vito; Silvia Bullitta; Helena Sepman; Girolama A Marfia; Diego Centonze
Journal:  Nat Rev Neurol       Date:  2015-11-20       Impact factor: 42.937

3.  LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex.

Authors:  Maria D Cirnaru; Antonella Marte; Elisa Belluzzi; Isabella Russo; Martina Gabrielli; Francesco Longo; Ludovico Arcuri; Luca Murru; Luigi Bubacco; Michela Matteoli; Ernesto Fedele; Carlo Sala; Maria Passafaro; Michele Morari; Elisa Greggio; Franco Onofri; Giovanni Piccoli
Journal:  Front Mol Neurosci       Date:  2014-05-27       Impact factor: 5.639

Review 4.  CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.

Authors:  Anna Pittaluga
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

5.  Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.

Authors:  Roberta Ricciarelli; Chiara Brullo; Jos Prickaerts; Ottavio Arancio; Carla Villa; Claudia Rebosio; Elisa Calcagno; Matilde Balbi; Britt T J van Hagen; Elentina K Argyrousi; Hong Zhang; Maria Adelaide Pronzato; Olga Bruno; Ernesto Fedele
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.